of VERU-111 shows comparable tumor inhibition with IV administered Docetaxel in PC3 prostate cancer cell xenograft model. In a xenograft model with Taxol-resistant PC3 cells, more than 6x inhibition was seen with VERU-111 with better safety profile in animals. While in vitro inhibition was in PC3 cel